CRISPR Therapeutics AG (CRSP) vs Doximity, Inc. (DOCS)
A side-by-side comparison of CRISPR Therapeutics AG and Doximity, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
CRSP
CRISPR Therapeutics AG
$55.43HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
DOCS
Doximity, Inc.
$27.93HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
Total return — CRSP vs DOCS
growth of $100 · dividends reinvested · last 5yCRSP -57.6% (-15.8%/yr)DOCS -46.2% (-11.7%/yr)DOCS compounded faster over this window
CRSP DOCS
CRSP vs DOCS: by the numbers
- •CRSP is the larger company ($5.35B vs $5.22B market cap).
- •DOCS is profitable (25.48% net margin) while CRSP runs a net loss (-3368.72%).
- •CRSP grew revenue faster over the past five years (37.32% vs 21.94% CAGR).
Metrics side by side
Valuation
| Metric | CRSP | DOCS |
|---|---|---|
| P/E ratio | N/A | 32.86 |
| Forward P/E | N/A | 20.73 |
| PEG ratio | N/A | 0.63 |
| P/S ratio | 399.21 | 7.97 |
| P/B ratio | 3.06 | 5.70 |
| EV / EBITDA | N/A | 23.44 |
| FCF yield | N/A | 5.73% |
Profitability
| Metric | CRSP | DOCS |
|---|---|---|
| Gross margin | -6537.01% | 88.07% |
| Operating margin | -16191.40% | 29.60% |
| Net margin | -3368.72% | 25.48% |
| ROE | -25.83% | 18.24% |
| ROIC | -21.12% | 15.35% |
Growth (annualized)
| Metric | CRSP | DOCS |
|---|---|---|
| Revenue CAGR (5Y) | 37.32% | 21.94% |
| EPS CAGR (5Y) | N/A | 54.32% |
| FCF CAGR (5Y) | N/A | 23.75% |
| Total return CAGR (5Y) | -13.01% | -18.53% |
Frequently asked
- Which has grown faster, CRSP or DOCS?
- Over the past five years, CRSP grew revenue faster — CRSP at a 37.32% CAGR versus DOCS at 21.94%.
- Is CRSP or DOCS more profitable?
- DOCS runs the higher net margin — CRSP at -3368.72% versus DOCS at 25.48%.
- How have CRSP and DOCS total returns compared?
- Over the past 5 years, CRSP delivered -13.01% and DOCS delivered -18.53% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Doximity P/E ratioCRISPR Therapeutics AG ROEDoximity ROECRISPR Therapeutics AG operating marginDoximity operating marginCRISPR Therapeutics AG revenue growthDoximity revenue growthCRISPR Therapeutics AG free cash flowDoximity free cash flow
CRISPR Therapeutics AG & Doximity appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.